|
1
|
Walther MM, Yang JC, Pass HI, Linehan WM
and Rosenberg SA: Cytoreductive surgery before high dose
interleukin-2 based therapy in patients with metastatic renal cell
carcinoma. J Urol. 158:1675–1678. 1997.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mickisch GH, Garin A, van Poppel H, de
Prijck L and Sylvester R: European Organisation for Research and
Treatment of Cancer (EORTC) Genitourinary Group. Radical
nephrectomy plus interferon-alfa-based immunotherapy compared with
interferon alfa alone in metastatic renal-cell carcinoma: A
randomised trial. Lancet. 358:966–970. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Flanigan RC, Salmon SE, Blumenstein BA,
Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N and Crawford
ED: Nephrectomy followed by interferon alfa-2b compared with
interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J
Med. 345:1655–1659. 2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Motzer RJ, Mazumdar M, Bacik J, Berg W,
Amsterdam A and Ferrara J: Survival and prognostic stratification
of 670 patients with advanced renal cell carcinoma. J Clin Oncol.
17:2530–2540. 1999.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Fallick ML, McDermott DF, LaRock D, Long
JP and Atkins MB: Nephrectomy before interleukin-2 therapy for
patients with metastatic renal cell carcinoma. J Urol.
158:1691–1695. 1997.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Hsieh JJ, Purdue MP, Signoretti S, Swanton
C, Albiges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal
cell carcinoma. Nat Rev Dis Primers. 3(17009)2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Choueiri TK, Xie W, Kollmannsberger C,
North S, Knox JJ, Lampard JG, McDermott DF, Rini BI and Heng DY:
The impact of cytoreductive nephrectomy on survival of patients
with metastatic renal cell carcinoma receiving vascular endothelial
growth factor targeted therapy. J Urol. 185:60–66. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Heng DY, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Culp SH, Tannir NM, Abel EJ, Margulis V,
Tamboli P, Matin SF and Wood CG: Can we better select patients with
metastatic renal cell carcinoma for cytoreductive nephrectomy.
Cancer. 116:3378–3388. 2010.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Manley BJ, Kim EH, Vetter JM, Potretzke AM
and Strope SA: Validation of preoperative variables and
stratification of patients to help predict benefit of cytoreductive
nephrectomy in the targeted therapy ERA. Int Braz J Urol.
43:432–439. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kerbl DC, McDougall EM, Clayman RV and
Mucksavage P: A history and evolution of laparoscopic nephrectomy:
Perspectives from the past and future directions in the surgical
management of renal tumors. J Urol. 185:1150–1154. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Walther MM, Lyne JC, Libutti SK and
Linehan WM: Laparoscopic cytoreductive nephrectomy as preparation
for administration of systemic interleukin-2 in the treatment of
metastatic renal cell carcinoma: A pilot study. Urology.
53:496–501. 1999.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Rabets JC, Kaouk J, Fergany A, Finelli A,
Gill IS and Novick AC: Laparoscopic versus open cytoreductive
nephrectomy for metastatic renal cell carcinoma. Urology.
64:930–934. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Eisenberg MS, Meng MV, Master VA, Stoller
ML, Rini BI, Carroll PR and Kane CJ: Laparoscopic versus open
cytoreductive nephrectomy in advanced renal-cell carcinoma. J
Endourol. 20:504–508. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Piccirillo JF and Feinstein AR: Clinical
symptoms and comorbidity: Significance for the prognostic
classification of cancer. Cancer. 77:834–842. 1996.PubMed/NCBI
|
|
17
|
Zlatev DV, Ozambela M, Salari K, Wang Y,
Mossanen M, Pucheril D, Ingham MD, Chung BI and Chang SL: Trends
and morbidity for minimally invasive versus open cytoreductive
nephrectomy in the management of metastatic renal cell carcinoma. J
Clin Oncol. 36 (Suppl 6)(S632)2018.
|
|
18
|
Gershman B, Moreira DM, Boorjian SA, Lohse
CM, Cheville JC, Costello BA, Leibovich BC and Thompson RH:
Comprehensive characterization of the perioperative morbidity of
cytoreductive nephrectomy. Eur Urol. 69:84–91. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nunez Bragayrac L, Hoffmeyer J, Abbotoy D,
Attwood K, Kauffman E, Spiess P, Wagner A and Schwaab T: Minimally
invasive cytoreductive nephrectomy: A multi-institutional
experience. World J Urol. 34:1651–1656. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zini L, Capitanio U, Perrotte P, Jeldres
C, Shariat SF, Arjane P, Widmer H, Montorsi F, Patard JJ and
Karakiewicz PI: Population-based assessment of survival after
cytoreductive nephrectomy versus no surgery in patients with
metastatic renal cell carcinoma. Urology. 73:342–346.
2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hanna N, Sun M, Meyer CP, Nguyen PL, Pal
SK, Chang SL, de Velasco G, Trinh QD and Choueiri TK: Survival
analyses of patients with metastatic renal cancer treated with
targeted therapy with or without cytoreductive nephrectomy: A
national cancer data base study. J Clin Oncol. 34:3267–3275.
2016.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Stewart GD, Aitchison M, Bex A, Larkin J,
Lawless C, Méjean A, Nathan P, Oades G, Patard JJ, Paul J, et al:
Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: A
question that may never be answered. Eur Urol. 71:845–847.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Pindoria N, Raison N, Blecher G,
Catterwell R and Dasgupta P: Cytoreductive nephrectomy in the era
of targeted therapies: A review. BJU Int. 120:320–328.
2017.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Shuch B, Hanley J, Lai J, Vourganti S, Kim
SP, Setodji CM, Dick AW, Chow WH and Saigal C: Urologic Diseases in
America Project. Overall survival advantage with partial
nephrectomy: A bias of observational data? Cancer. 119:2981–2989.
2013.PubMed/NCBI View Article : Google Scholar
|
